• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


Short to Mid-Term f/u of New US Patients

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Adequate
Application Number P150030 / PAS002
Date Current Protocol Accepted 12/07/2018
Study Name Short to Mid-Term f/u of New US Patients
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Historical Control
Analysis Type Analytical
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description The study design is prospective cohort, new enrollment.
Study Population Description The study population is comprised of US patients who receive the device in the post market environment. The comparator group is comprised of patients in the European premarket cohort.
Sample Size A total of 183 study subjects will be enrolled.
Data Collection The primary endpoint is overall study success at 3 years post procedure. Success is defined the same way it was in the premarket cohort, to allow comparison. Overall Success is defined as:

No component revision, and

Modified Harris Hip Score (mHHS) of at least 80 points, and

No radiographic failure, defined as:

No radiolucencies greater than 2 mm in 50% or more in any of the cup or stem zones, no femoral or acetabular subsidence greater than or equal to 5 mm from baseline, and no acetabular cup inclination changes greater than 4 degree.

Follow-up Visits and Length of Follow-up Patients will be followed for 3 years
Interim or Final Data Summary
Interim Safety Information Number of study sites enrolled A total of 3 study sites have been enrolled in the study.

Number of subjects enrolled A total of 2 study subjects have been enrolled.

Follow-up rate The follow-up rate is 100% for only 2 patients.

Summary of Interim Results Interim data will be released in July 2020.

Strengths and Weaknesses A strength of the study is its adequate power to detect differences in short-term device survival between the US post-market cohort and the European ore-market cohort. A weakness of the study is the absence of long-term follow-up to assess long-term device performance.

Short to Mid-Term f/u of New US Patients Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
six month report 04/17/2017 04/17/2017 On Time
one year report 10/17/2017 10/12/2017 On Time
18 month report 04/17/2018 04/16/2018 On Time
two year report 10/17/2018 10/15/2018 On Time
three year report 10/17/2019 10/15/2019 On Time
four year report 10/16/2020 10/16/2020 On Time
five year report 10/16/2021    
final report 12/30/2022    

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources